Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04658472 · ClinicalTrials.gov registry record · Phase 2
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 2 study, sponsored by Bioverativ, a Sanofi company.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT04658472 is a Phase 2 study that has completed, run by Bioverativ, a Sanofi company. The registered enrollment target is 98 participants.
The verdict
NCT04658472, a Phase 2 study, has completed, sponsored by Bioverativ, a Sanofi company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
Primary Objectives: * Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive * Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary Objectives: * Part A: * Safety and tolerability of SAR445088 in CIDP * Immunogenicity of SAR445088 * Efficacy of SAR445088 with overlapping SOC (SOC-Treated group) * Part B: * Durability of efficacy during long-term treatment with SAR445088 in CIDP * Long-term immunogenicity of SAR445088 in CIDP
Interventions
- DRUG SAR445088 (IV)
- DRUG SAR445088 (SC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04658472
The ClinicalTrials.gov registry entry for NCT04658472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ, a Sanofi company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SAR445088 (IV) is the first listed.
NCT04658472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04658472 about?
NCT04658472 is a clinical study titled "Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". Primary Objectives: * Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive * Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary Objectives: * Part A: * Safety and tolerability of SAR445088 ...
What is the current status of trial NCT04658472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2021-04-28. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT04658472?
The interventions under investigation include: SAR445088 (IV) (DRUG), SAR445088 (SC) (DRUG).
Who is sponsoring clinical trial NCT04658472?
This trial is sponsored by Bioverativ, a Sanofi company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.